When someone has lupus for decades, developing a completely different autoimmune disease seems unlikely, yet a striking case report reveals how two separate immune conditions can overlap in ways that challenge everything doctors thought they knew about autoimmune disease. A 74-year-old Japanese woman with a 39-year history of systemic lupus erythematosus (SLE) developed granulomatosis with polyangiitis (GPA), a rare form of vasculitis that inflames small blood vessels, forcing doctors to rethink how these distinct immune disorders interact. What Happens When Lupus and Vasculitis Overlap? The patient's case is unusual because SLE and GPA operate through completely different immune mechanisms. In lupus, the immune system produces antibodies that attack the body's own nuclear material and deposit in various tissues, causing widespread inflammation. In GPA, a different set of antibodies called ANCA (antineutrophil cytoplasmic antibodies) activate infection-fighting white blood cells called neutrophils, which then attack the walls of small blood vessels. The woman initially presented with a persistent cough, fever, and fatigue that didn't respond to antibiotics. Imaging revealed lung damage including bronchiectasis (permanent airway damage), nodular lesions, and sinus inflammation. Her kidney function rapidly declined, with her serum creatinine rising to 1.26 mg/dL, along with blood and protein in her urine, suggesting kidney involvement. Blood tests showed a marked elevation of anti-MPO-ANCA antibodies at 182 U/mL, far exceeding the normal range of less than 3.5 U/mL. MPO (myeloperoxidase) is an enzyme found in neutrophils, and when antibodies attack it, they trigger the cascade of inflammation characteristic of GPA. A lung biopsy confirmed the diagnosis, revealing necrotizing granulomas with vascular injury consistent with vasculitis. Why Does Impaired Immune Cleanup Matter? The key to understanding this overlap lies in a process called NET clearance. When neutrophils die, they release web-like structures called neutrophil extracellular traps (NETs) that contain proteins like PR3 (proteinase-3) and MPO. Normally, the body cleans up these NETs efficiently. However, in lupus patients, this cleanup process is impaired, allowing NETs to accumulate in tissues. "Although the mechanism of SLE is not fully understood, several studies have reported impaired clearance of neutrophil extracellular traps (NETs) containing PR3 and MPO, leading to small vessel injury. Moreover, excessive or persistent NETs have been linked to ANCA induction. These abnormalities in NET clearance and ANCA induction may offer a plausible mechanistic basis for SLE-AAV overlap syndrome," the study authors explained. This accumulation of NETs may be the bridge between the two diseases. When NETs persist in tissues, they expose the immune system to PR3 and MPO repeatedly, potentially triggering the production of ANCA antibodies. In this patient's case, decades of impaired NET clearance from lupus may have set the stage for GPA to develop later in life. How Doctors Treated This Complex Case - High-Dose Corticosteroids: The patient received intravenous methylprednisolone to rapidly suppress the acute vasculitis inflammation in her lungs and kidneys. - Maintenance Corticosteroids: Oral prednisolone was continued to prevent relapse of both her lupus and the newly diagnosed GPA. - B-Cell Targeted Therapy: Rituximab, a monoclonal antibody that depletes B cells, was administered to address the antibody-producing cells driving both diseases. The treatment strategy worked. Seven months after starting therapy, her serum creatinine improved to 0.72 mg/dL, indicating restored kidney function. Her lung lesions and bronchial wall thickening also improved significantly. What Does This Mean for Patients With Lupus? This case highlights an important clinical lesson: patients with long-standing lupus should be monitored for signs of vasculitis, particularly if they develop new respiratory symptoms, sinus infections, or rapid kidney function decline. The overlap of SLE and GPA is rare, but recognizing it early is critical because GPA requires aggressive immunosuppressive treatment to prevent permanent organ damage. The case also underscores why understanding the underlying immune mechanisms matters. Rather than viewing autoimmune diseases as completely separate entities, this overlap suggests they may share common pathways, particularly around how the body handles dead immune cells and the debris they leave behind. Future research into NET clearance could potentially identify patients at higher risk for developing multiple autoimmune conditions, allowing for earlier intervention and better outcomes.
